Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Cortical Lesion Burden Indicative of Multiple Sclerosis Disability, Progression

the Neurology Advisor take:

Cortical lesions are known to affect cognitive and physical disability in multiple sclerosis (MS), and assessing such burden may help to better understand disease progression and treatment.

Daniel M. Harrison, MD, of the University of Maryland, and colleagues conducted an observational clinical imaging study to better understand the clinical relevance of measures of cortical lesion burden in MS using high-field MRI.

Thirty-six people with MS (30 with relapsing-remitting, six with secondary or primary-progressive) and 15 healthy controls participated in the imaging study, which used 7-Tesla MRI performed with 0.5-mm isotropic resolution magnetization-prepared rapid acquisition gradient echo (MPRAGE) and whole-brain, 3-dimensional, 1.0-mm isotropic resolution magnetization-prepared, fluid-attenuated inversion recovery (MRPFLAIR).

Lesions were classified as leukocortical, intracortical, or subpial. Physical disability was measured by the Expanded Disability Status Scale (EDSS) and cognitive disability was measured with the Minimal Assessment of Cognitive Function in MS battery. Brain structure volumes and white matter lesion volume were also reported.

Researchers reported that cortical lesions were found in 35 of 36 participants (97%), with a median of 16 lesions per person (range 0-99). Leukocortical lesion volume was found to correlate with white matter lesion volume (P=0.50; P=.003), but not with cortical volume. Subpial leasion volume inversely correlated with cortical volume (P=-0.36; P=.04) but not with white matter lesion volume. Total count and volume of cortical lesions (median) were significantly increased in participants with EDSS scores of 5.0 or more compared to those with scores less than 5.0 (count: 29 [11-99] vs 13 [0-51]; volume: 2.81 × 10−4 [1.30 × 10−4 to 7.90 × 10−4] vs 1.50 × 10−4 [0 to 1.01 × 10−3]) and in cognitively impaired participants compared to unimpaired participants (count: 21 [0-99] vs 13 [1-54]; volume: 3.51 × 10−4 [0 to 1.01 × 10−4] vs 1.19 × 10−4 [0 to 7.17 × 10−4]).

Cortical lesion volume correlated with EDSS scores more so than white matter lesion volume (P=0.59 vs 0.36). Increasing cortical lesion volume aligned with a 3-fold increase in odds of cognitive impairment (odds ratio [OR], 3.36; 95% CI, 1.07-10.59; P = .04) and a 14-fold increase in odds after adjustment for white matter lesion volume and atrophy (OR, 14.26; 95% CI, 1.06-192.37; P = .045).

Overall, leukocortical lesions had the greatest effect on cognition (OR for log [leukocortical lesion volume], 9.65; 95% CI, 1.70-54.59, P = .01), differing from subpial lesions. Assessing lesion burden may therefore provide a better understanding of MS disability and disease progression and may indicate target areas for treatment.

Cortical lesions (CLs) contribute to physical and cognitive disability in multiple sclerosis (MS). Accurate methods for visualization of CLs are necessary for future clinical studies and therapeutic trials in MS.

Daniel M. Harrison, MD, of the University of Maryland, and colleagues evaluated the clinical relevance of measures of CL burden derived from high-field magnetic resonance imaging (MRI) in MS.An observational clinical imaging study was conducted at an academic MS center. Participants included 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive) and 15 healthy individuals serving as controls. The study was conducted from March 10, 2010, to November 23, 2012, and analysis was performed from June 1, 2011, to September 30, 2014.

Story Source: The above story is based on materials provided by NEUROLOGYADVISOR
Note: Materials may be edited for content and length

Go to Newer News Go to Older News